Objective: The purpose of this investigation was to perform a cost-effectiveness analysis of adjunctive oral and intravenous proton pump inhibitor (PPI) therapies for patients with acute peptic ulcer-related bleeding of sufficient severity to warrant hospitalization.
O f the estimated 300,000 hospital admissions each year in the United States due to upper gastrointestinal bleeding, approximately 5-10% of patients die as a result of bleeding-related complications (1) . Mortality rates at least this high have been noted in other countries as well (2) . This mortality rate has remained relatively unchanged for at least 30 yrs, pos-sibly due to the increasing number of patients with concomitant illnesses and, until relatively recently, the lack of effective therapies (3) . Peptic ulcer-related bleeding, which is responsible for Ͼ50% of all causes of upper gastrointestinal bleeding, may be limited or stopped by a variety of therapeutic interventions including endoscopy (4) . Endoscopy as a therapeutic modality did not begin to see widespread use until the 1980s (5) , so it is possible that mortality rates will decrease in future epidemiologic investigations of upper gastrointestinal bleeding as a result of this modality.
Pharmacologic modalities to limit bleeding and transfusion requirements have been used in conjunction with therapeutic endoscopy for the management of patients with peptic ulcer-related bleeding. Although the histamine-2-antagonists are of questionable efficacy for acute peptic ulcer-related bleeding (6) , proton pump inhibitors (PPIs) have demonstrated efficacy in preventing rebleeding and reducing transfusion requirements in several randomized controlled trials involving Ͼ1,000 patients (7) . Since both endoscopy and the PPIs have associated costs as well as risks and benefits, economic evaluations are needed to help define their role in patients with peptic ulcer-related bleeding. The potential savings associated with successful interventions are substantial since the costs associated with peptic ulcer-related bleeding are approximately $1.25 billion yearly in the United States, assuming that such bleeding accounts for at least half of all causes of upper gastrointestinal hemorrhage (8) .
The need for economic evaluations of competing strategies including PPIs as adjunctive therapy to endoscopy for peptic ulcer-related bleeding has been recognized (9) , and several investigations have been published (10 -13) . The earliest of these economic evaluations was designed to compare endoscopic treatment regimens, so the value of adjunctive PPI therapy was not addressed (10) . Of the recent investigations that have evaluated the cost-effectiveness of adjunctive PPI therapy, one was conducted from the perspective of a public health organization in Hong Kong (11) and the other from a third-party payer perspective in Canada (12) . The only investigation conducted from the perspective of a third party payer in the United States evaluated four competing strategies: usual care (repeat endoscopy only if clinical evidence of recurrent bleeding), usual care plus highdose intravenous PPI therapy, repeat endoscopy in all patients at 24 hrs, and selective endoscopy at 24 hrs based on a validated scoring system relative to risk of recurrent bleeding (13) . The investigators concluded that the selective endoscopy strategy and the adjunctive use of PPIs were the most cost-effective strategies with the preferred approach depending on the cost of intravenous PPI therapy.
Determining the preferred strategy for managing patients with acute peptic ulcer-related bleeding has become more complicated as the cost of PPI therapy decreases and with recent studies suggesting the effectiveness of oral (14 -16) as well as intravenous (17) (18) (19) route of administration. Therefore, the purpose of this investigation was to perform a costeffectiveness analysis of adjunctive oral and intravenous PPI therapies for patients with acute peptic ulcer-related bleeding of sufficient severity to warrant hospitalization. The analysis was conducted from the perspective of a university teaching hospital in the United States.
METHODS
Diagnostic/Treatment Scenarios. Human subjects' approval was obtained before conducting the study. For the purpose of this analysis, it was presumed that confirmatory endoscopy was performed within 24 hrs of the preliminary clinical diagnosis of acute peptic ulcer-related bleeding. Furthermore, it was assumed that all patients would require Ն24 hrs of hospitalization. Based on clinical presentation and endoscopic findings, patients were initially considered to require immediate surgery, observation only (e.g., stable patients with clean bases or flat spots), or endoscopy with or without PPI therapy. The percentages of patients needing immediate surgery, observation, or endoscopic/PPI therapy were based on data obtained from three of the six prospective, randomized, placebo-controlled trials involving PPI therapy that published this information (14, 15, 17) . The findings of these studies were consistent with approximately 1% of patients requiring immediate surgery, 63-67% (66% used as baseline figure for this analysis) of patients with clean bases or flat spots requiring no therapy, and the remainder receiving endoscopic and/or PPI therapy. It was assumed that diagnostic endoscopy was used (or at least attempted to help determine the need for immediate surgery). The probability of death related to surgery was based on one of the more recent randomized, placebocontrolled investigations and expert opinion (3, 17) . The baseline probability estimates for all variables in this investigation are listed in Table 1 .
The randomized, controlled investigations that served as the basis for most of the probabilities used in this analysis typically excluded patients with clean bases or flat spots (14 -19) . The latter patients may be discharged in Ͻ24 hrs (20) , but older, unstable patients at a higher risk for complications may require a few days of hospitalization. Since the length of stay of patients with mild forms of bleeding may range from 0 (clean base) to 3 (flat spot) days (3), for the baseline case in this analysis, patients with clean bases or flat spots were estimated to require hospitalization on a patient ward for 2 days for observation only (no medications or other therapeutic interventions).
The remainder of patients receiving endoscopy with or without PPIs were the focus on this economic analysis and served as the basis for the four clinical scenarios: scenario 1, diagnostic endoscopy with oral PPI therapy; scenario 2, diagnostic and therapeutic endoscopy with high-dose intravenous PPI therapy; scenario 3, diagnostic and therapeutic endoscopy available with oral PPI therapy; and scenario 4, diagnostic and therapeutic endoscopy (no PPI therapy).
The first scenario presumed that therapeutic endoscopy was not possible and that therapy was limited to oral PPI therapy (40 mg twice daily of omeprazole or the equivalent dose of another PPI for 5 days). Of note, all of the randomized, double-blind, placebocontrolled trials that served as the basis for the clinical scenarios in this economic analysis used the PPI omeprazole (14, 15, 17) . However, although the exact dose equivalencies of the various PPIs is open to debate, it seems likely that the beneficial effects of agents within this class would be similar based on the common mechanism of action (21) . This first scenario is probably least likely to occur in actual practice at a tertiary care institution in the United States. In addition to its use as a diagnostic modality, endoscopy as a therapeutic intervention has been demonstrated to reduce persistent/recurrent bleeding, the need for surgery, and mortality rate in two metaanalysis (22, 23) . Therefore, endoscopic intervention is the procedure of choice for patients who have had substantial bleeding and/or are at high risk for rebleeding (24) . Nevertheless, this scenario was included as a possible option since it was the basis of one large randomized, placebo-controlled investigation, and its costeffectiveness relative to other treatment options is relatively unstudied (14) .
In the investigation used as the basis for this first scenario, the average length of hospital stay was 5.5 Ϯ 2.1 days. Although this study did not discuss how much of this time was spent in the intensive care unit vs. a ward, other published information suggests that these patients would need to spend 1 day in the intensive care unit (3). Therefore, it was assumed that the first day would be spent in the intensive care unit and the remaining 4.5 days would be on a ward.
In the second scenario, patients who had endoscopic findings consistent with a substantial risk of persistent or recurrent bleeding (i.e., active bleeding, visible vessel, or adherent clot) were assumed to be hospitalized and given both endoscopic and high-dose intravenous PPI (80 mg bolus followed by 8 mg/hr for 72 hrs) therapies. In a recently published trial involving patients who received both diagnostic and therapeutic endoscopic interventions in conjunction with high-dose intravenous PPI therapy (17) , the median length of hospital stay was 4 days. As in the first scenario, it was assumed that these patients would require 1 day of stay in the intensive care unit since .109 Recurrent bleeding after therapeutic endoscopy (no PPI)
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the actual breakdown of unit vs. ward was not specified in the published article (17); the remaining 3 days were considered to be on a hospital ward.
In the third scenario, it was assumed that endoscopy was available for diagnostic and therapeutic purposes and that concomitant oral PPI therapy (40 mg twice daily of omeprazole or equivalent for 5 days) was used. Length of stay for this scenario was based on a study using this therapeutic approach that found an average length of hospital stay of 4.6 Ϯ 1.1 days (15) . One day of this stay was presumed to occur in the intensive care unit and the remaining time on a ward.
In the fourth scenario, it was assumed that both diagnostic and therapeutic endoscopy was available, but PPI therapy was not used. Length of stay figures used in this scenario were based on a study in which this approach was used (the placebo group of the study) (17) . Since the median length of stay was 5 days in the study, one day of this stay was presumed to occur in the intensive care unit and the remaining time on the ward.
In the studies that formed the basis for the clinical scenarios, patients were not followed for Ͼ30 days so that was the time frame for this analysis (15) (16) (17) . A 30-day outcome is commonly used as the limit to which rehospitalization or death related to acute upper gastrointestinal hemorrhage is likely to occur (20) . Furthermore, it has been estimated that 90% of patients with recurrent bleeding experience this within 72 hrs of hospital admission (13) .
In addition to length of stay, another factor representing the efficacy of therapeutic endoscopy and PPI therapy (if given) included the need for, and volume of, red blood cell transfusion (RBC). Other blood products were not considered since they are reserved for specific deficiencies (e.g., fresh frozen plasma for clotting factor losses, platelets for thrombocytopenia) associated with more severe hemorrhage. Furthermore, use of blood products was not the primary end point (recurrent bleeding usually was) in published randomized, controlled investigations of PPIs for acute peptic ulcer-related bleeding, and a full delineation of the products administered was not provided (14 -19) .
With one exception, the proportion of patients receiving RBCs transfusions and the amount of RBCs transfused were derived from randomized, placebo-controlled studies that served as the basis for each of the clinical scenarios. The exception was the third scenario in which diagnostic and therapeutic endoscopy was used in conjunction with oral PPI therapy. Although the study that served as the basis for this scenario had information on length of stay and the proportion of patients requiring transfusion, it did not detail the amount of RBCs administered in the treatment and placebo groups (15) . Similarly, the amount of RBCs administered was not discussed in another publication with similar methodology (16) . So, although the proportion of patients requiring transfusion was obtained from the trial that served as the basis for the third scenario (15) , the volume of RBCs transfused was presumed to be the same as patients receiving high-dose intravenous PPI therapy in the second scenario.
The possibility of adverse effects to RBC administration was not considered in the final model. The more severe adverse effects associated with blood product administration that are most likely to have a substantial cost impact are rare. A preliminary analysis was conducted in which major transfusion reactions and infection risks were included in the decision analysis. Inclusion of such adverse effects did not substantially affect the results of the analysis but added substantial complexity to the decision tree. Therefore, this component was left out of the final model. Serious adverse effects associated with PPI therapy are also very unlikely and were not considered in the analysis (7) . The likelihood of serious complications associated with endoscopy was uncommonly reported in recent prospective randomized studies investigating PPI therapy (15) (16) (17) (18) (19) , and this is at least partially a function of improved endoscopic techniques (25) . In one of the few times in which perforation was noted to occur (17), surgical intervention was required. For this analysis, it was assumed that patients taken to surgery following endoscopy would include those patients with endoscopyrelated complications as well as those patients in whom endoscopy failed to control bleeding. Similarly, the incidence of death following surgery was considered to include patients with endoscopy-related complications and those who failed endoscopic therapy. The incidence of death was derived from the recent randomized controlled trials involving PPI therapy (15) (16) (17) (18) (19) as well as a recent investigation that looked at the mortality rate associated with perforated peptic ulcers (26) . Figure   1 shows the truncated decision tree with the four clinical scenarios being evaluated.
Cost Assumptions. The baseline cost assumptions for patients hospitalized with suspected upper peptic ulcer-related bleeding involved costs related to endoscopy, length of stay, PPI therapy, blood transfusions, surgery, and death. The costs for endoscopy (both diagnostic and treatment) and duration of hospitalization (ward and intensive care unit) were derived from a previous economic investigation involving a university teaching hospital, which compared a medical/surgical approach to endoscopy for patients with peptic ulcer-related bleeding (10) . The baseline cost for therapeutic endoscopy presumed that the thermal type method was used, since this modality is at least comparable to other techniques such as laser or injection (3) . The literature-derived costs associated with endoscopy were updated using the consumer price index.
All of the large prospective, randomized, controlled investigations using a PPI for acute peptic ulcer-related bleeding were conducted outside the United States and involved omeprazole (14 -19) . Since there is no intravenous formulation of omeprazole that is commercially available in the United States, the cost of PPI therapy was based on intravenous pantoprazole with presumed dose equivalency. Although the cost of this agent varies based on purchasing agreements, a baseline cost of $3 for a 40-mg vial was used for this analysis. For oral therapy, a cost of $0.30 for 40-mg dosage form was used in the analysis. Both the intravenous and oral costs were based on expected purchase costs at a large tertiary care facility. Another $10 was added to the intravenous PPI cost for the tubing and pump administration costs.
No adverse effect-related costs due to the PPI were included in this analysis, because no significant adverse effects have been reported with these agents when used for acute peptic ulcer-related bleeding. This is not surprising given the relative lack of adverse effects associated with PPIs regardless of indication and particularly when used for short periods of time (e.g., Ͻ1 wk). The problems that might occur (e.g., headache, nausea) would be expected to be transient in nature and have minor cost consequences (27) .
Only patients with more serious forms of bleeding (i.e., active bleeding, visible vessel, adherent clot) were presumed to require RBC transfusions. The cost of packed RBCs was based on one of five published investigations of blood product costs (28 -32) . The study was chosen since its inpatient, tertiary care perspective (all hospitals were level I or II trauma centers) was similar to that of this investigation (28) . The baseline cost assumption extracted from this study was adjusted to current dollars based on the consumer price index.
The final costs in the model were related to surgery and death. The cost of surgery was based on estimated Medicare cost for bowel perforation, which includes costs associated with length of stay, blood transfusions, and medications (13) . The cost of death (estimated resuscitation costs) was $1,000. Table 2 lists the baseline cost estimates used in the decision tree and sensitivity analyses. All baseline costs were decreased and increased by 50% during one-way sensitivity analyses (with threshold analyses) to test the robustness of the findings. Two-way sensitivity analysis was used to compare the various intravenous and oral PPI scenarios. All other costs related to acute peptic ulcer-related bleeding, such as those related to the patient being seen in an emergency department, were presumed to be the same for all scenarios and were not included in this analysis. Discounting was not considered to be necessary since the costs and consequences were expected to occur within the same short time frame of the clinical scenarios (i.e., 1 month).
Cost-Effectiveness Analysis. The three published cost-effectiveness studies that included at least one scenario involving PPI therapy used episodes of bleeding averted (11) (12) , or in one case episodes of bleeding, surgery, or death averted (13) , as the primary effectiveness outcome. In this investigation, effectiveness was primarily evaluated in terms of episodes of bleeding averted based on the studies underlying the clinical scenarios (14, 15, 17) . However, quality-adjusted life years (QALYs) were considered as a secondary measure of effectiveness of the various scenarios. The QALYs used for the cost-effectiveness calculations were obtained from a source that listed QALY values for upper endoscopy (0.5675), gastrointestinal hemorrhage requiring hospitalization (0.5), inpatient treatment of a complicated ulcer (0.4902), and inpatient treatment of a complicated ulcer that includes surgery (0.4642) (33) . The upper endoscopy QALY was only used as an effectiveness measure for patients who had diagnostic endoscopy on admission with no additional therapy (i.e., patients at low risk for bleeding based on endoscopic findings). The inpatient treatment of a complicated ulcer QALY was used for any pathway in which patients had recurrent bleeding after the initial episode, except for those patients with recurrent bleeding who underwent surgery who were assigned the QALY of 0.4642, or those patients with recurrent bleeding who ultimately died and who were assigned a QALY of 0. The gastrointestinal hemorrhage requiring hospitalization QALY was used as an intermediate level QALY (between 0.5675 and 0.4902) for patients who had no bleeding after the initial therapeutic regimen was instituted. The decision analysis was performed using TreeAge Software (Williamstown, MA).
RESULTS
The use of an intravenous PPI in conjunction with therapeutic endoscopy (i.e., scenario 2) was the dominant approach as evidenced by both superior effectiveness and lower cost based on the probability estimates and cost variables used in the sensitivity analysis. The findings were similar using either episodes of bleeding averted or QALYs for the effectiveness measure ( Table 3 ). During the threshold analysis, the only change in the decision tree that would alter the optimal choice of therapy occurred if the cost of length of stay was lower with the oral PPI regimens compared with the high-dose intravenous scenario, or vice versa. For example, for the oral PPI regimen in scenario 3 to be the most cost-effective choice in terms of bleeding episodes averted, the cost of length of stay of the oral therapy regimen would have to decrease from the baseline cost of $2,916 to Ͻ$2,670, whereas the baseline length of stay costs associated with the intravenous regimen in scenario 2 were unchanged or decreased. Similarly, for the oral PPI regimen in scenario 1 to be the optimal choice, the cost of length of stay associated with the oral PPI approach would have to decrease from a baseline cost of $3,357 to Ͻ$1,834, whereas the baseline length of stay costs in scenario 2 were unchanged or decreased. Changing the intravenous and oral PPI therapy costs over the range of values used in the sen- sitivity analysis did not affect the dominance of the intravenous approach.
DISCUSSION
Of the three cost-effectiveness investigations evaluating the use of high-dose intravenous PPI therapy for acute peptic ulcer bleeding (11) (12) (13) , only one was conducted from the perspective of a health care system in the United States (13) . The latter study evaluated two scenarios involving second-look endoscopy (reendoscopy in all patients vs. re-endoscopy in patients at high risk for rebleeding), a scenario in which high-dose intravenous PPI therapy was given as an adjunct to therapeutic endoscopy and a usual care scenario in which patients only had a second endoscopy if signs of rebleeding occurred (no high-dose PPI) (13) . The selective second-look endoscopy was the most effective and least costly strategy, but the PPI scenario became the dominant strategy when the risk of rebleeding with PPI therapy was Ͻ9% and the cost of the PPI was Ͻ$10 per day. The costeffectiveness of oral PPI therapy was not considered in the investigation.
In this analysis, which included oral and intravenous PPI options, the most cost-effective scenario involved the use of high-dose intravenous PPI therapy in conjunction with therapeutic endoscopy to control bleeding. The most costly scenario involved hospitalization without concomitant PPI therapy. Although the findings were robust with respect to the sensitivity analysis, the actual differences between the costs and effectiveness of the oral and intravenous regimens were relatively small (scenarios 2 and 3 in Table  3 ). If the cost of length of stay was assumed to be lower with the oral regimen, or if the cost of the intravenous regimen were higher, the two routes of administration would yield similar cost-effectiveness values. The former scenario seems unlikely, since the rates of stay were quite similar in the studies that served as the basis for each of the clinical scenariosmedian of 4 days for intravenous therapy (17) and mean of 4.6 Ϯ 1.1 days for oral therapy (15) . Similarly, the purchase cost of the intravenous agent would need to be beyond the range considered in this study (i.e., it would have to be greater than $308 for a 3-day course) for the oral and intravenous regimens to be equally costeffective.
The length of stay and costs associated with suspected peptic ulcer-related bleed-ing are related to prompt diagnosis and, if needed, therapeutic interventions. Diagnostic endoscopy was performed within 12 hrs of admission in two of the studies that formed the basis for the clinical scenarios in this cost-effectiveness analysis (14, 15) and within 24 hrs in the third (17) . Using this approach, approximately two thirds of patients were found to require no therapeutic intervention (i.e., they had clean bases or flat spots) but were still hospitalized for 0 -3 days for observation. Although the number of patients requiring hospitalization might decrease with earlier endoscopy (34), they would not alter the conclusions of this cost-effectiveness analysis since it was assumed that the proportion of patients having diagnostic endoscopy was the same for each of the scenarios.
In this cost-effectiveness analysis, patients considered to have a high risk of rebleeding based on endoscopy were those with active bleeding, visible vessels (bleeding or nonbleeding), and adherent clots. These were the patients who were included as high risk based on the investigations that served as the basis for the scenarios (14, 15, 17) . It could be argued that patients with nonbleeding visible vessels or adherent clots might not generate the same benefit from a combined therapeutic endoscopy plus high-dose PPI regimen as patients with more active bleeding. However, a single-blind randomized trial involving 156 patients found recurrent bleeding in 9% of patients receiving high-dose intravenous omeprazole therapy compared with no patients receiving the combination therapy approach (p ϭ .01) (35) . Although the trial lends further support to a combined therapeutic approach, the relatively low percentage of rebleeding in patients receiving omeprazole therapy alone was surprising. The author of an editorial accompanying the published investigation warned clinicians to be suspect of this finding until further studies were performed but concluded that the addition of the high-dose intravenous PPI therapy to therapeutic endoscopy was warranted in patients with nonbleeding visible vessels or adherent clots (36) .
The primary study limitations are related to the published literature on which the assumptions of the economic analysis were based. For example, patients with clean bases or flat spots were not considered to require therapeutic endoscopy or high-dose PPI therapy since this approach was not used in the published trials. Additionally, in consensus guidelines published after this economic analysis was performed, there was a unanimous vote (level A recommendation) that low-risk stigmata are not an indication for endoscopic hemostasis (37) . Continuous infusion intravenous PPI therapy was recommended by a unanimous vote (level A recommendation) but only in patients who have undergone endoscopic therapy. The consensus group split on whether high-dose PPI therapy should be used in patients awaiting endoscopy and ultimately said it could be "considered" (level C recommendation). Fully two thirds of the patients in this economic analysis were presumed to have clean bases or flat spots on diagnostic endoscopy; unnecessary endoscopic or high-dose PPI therapy would only add to the costs and not to the benefits (i.e., it would not be a costeffective) in these patients. Since this analysis assumed that all patients received diagnostic endoscopy, it is unknown if high-dose intravenous PPI therapy while awaiting endoscopy is costeffective.
All of the major prospective, randomized, placebo-controlled investigations of PPI therapy for acute peptic acid-related bleeding were conducted in countries outside of the United States (14 -19) . Therefore, it was assumed that the efficacy of these medications, as based on recurrent bleeding, length of stay, and transfusion requirements, would be applicable in this country. Of particular importance is the presumption that the proportion of change in these variables between treatment and no-treatment groups is consistent across populations. Additional assumptions are required with respect to the cost-effectiveness determinations based on QALYs that were used as a secondary measure of effectiveness, since the QALYs were not derived from the same studies used to determine the probabilities for the clinical scenarios. However, the consistency of the findings for both effectiveness measures, as well as the wide range of probabilities and costs used in the sensitivity analysis, supports the findings of this investigation.
The RBC transfusion cost for this analysis was based on one of several economic investigations specifically designed to estimate RBC transfusion costs (28 -32) . The study was chosen since the cost figures were derived from the standpoint of an inpatient tertiary care facility, which is the same perspective as this investigation (28) . Other studies that found higher transfusion costs were conducted in cancer patients and included a number of testing and preparation costs that would not be routinely used in patients requiring transfusion for acute peptic ulcer-related bleeding or surgical procedures (31, 32) . Nevertheless, it could be argued that the cost figure used is conservative since it doesn't take into account additional costs that may be required to purchase such products during the periodic shortages that occur due to donation and shelf-life issues. Furthermore, the blood product cost did not include issues related to adverse effects such as infectious disease transmission, which rarely occur but have potentially life-threatening consequences (38) . These costs were not included in the final decision model based on the minimal impact of their inclusion in a preliminary analysis. However, even if the risks were deemed to be substantial, their inclusion would only increase the economic advantages associated with high-dose intravenous PPI therapy due to the lower risk of recurrent bleeding associated with this approach.
This analysis also presumed that other options for acute peptic ulcer-related bleeding were either not used (e.g., angiographic therapy) or were required in a relatively small percentage of patients (e.g., operative interventions). This assumption seems reasonable for angiography and increasingly likely for surgery given advancements in endoscopic techniques (3, 25) . In all of the recent investigations of PPI therapy for acute peptic ulcer-related bleeding, surgery was required in Յ1% of patients on admission and much less than that after endoscopic and/or PPI interventions (14 -19) .
A final study consideration relates to product availability. In the United States, an injectable omeprazole product is not commercially available, and all of the randomized controlled trials that served as the basis for the clinical scenarios in this study used omeprazole as the PPI for acute peptic ulcer-related bleeding. Intravenous pantoprazole is available, but it does not have published evidence of effectiveness based on adequately powered double-blind, placebo-controlled trials, nor does it have a Food and Drug Administration indication for acute peptic ulcer-related bleeding. Based on a common mechanism of action, as well as comparative information for other indications, it seems reasonable to assume that the PPIs would be equally efficacious in equipotent doses (7, 27) . Furthermore, highdose intravenous pantoprazole is commonly used for acute peptic ulcer bleeding in Canada (12) . However, additional research involving injectable forms of PPIs other than omeprazole would help clarify this issue, particularly with respect to equipotent dosing issues.
CONCLUSION
High-dose intravenous PPI therapy in conjunction with therapeutic endoscopy is the most cost-effective approach in patients with acute peptic ulcer bleeding who are at high risk for rebleeding based on endoscopic findings. The findings were robust using the range of values tested by sensitivity analysis. However, if the purchase cost of the intravenous PPI therapy was substantially higher than the value used in this investigation, the costeffectiveness advantage of the intravenous compared with the oral regimen would be lost assuming therapeutic endoscopy was used with both agents.
ADDENDUM
As the galley proofs for this article were being reviewed, another study investigating the cost effectiveness of highdose intravenous proton pump inhibitor therapy for acute peptic ulcer bleeding was published (Barkun AN, Herba K, Adam V, et al: High-dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcers in the USA and Canada: A cost-effectiveness analysis. Aliment Pharmacol Ther 2004; 19:591-600). The study was conducted from the perspective of a third-party payer in both United States and Canadian healthcare systems. Similar to the findings of the current investigation, adjunctive high-dose intravenous proton pump inhibition for 3 days following therapeutic endoscopy was found to be cost effective compared with no high-dose inhibition. 
